SOCS3: A potential therapeutic target for many human diseases

Yaoxue Xuebao

Volumn 46, Issue 7, 2011, Pages 747-752

  Xu, Wen Pin ^a   Li, Wei Dong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Inflammation; Obesity; Potential therapeutic target; SOCS3; Tumor; Virus infection

Indexed keywords

BIOLOGICAL MARKER; SUPPRESSOR OF CYTOKINE SIGNALING 3;

DISEASE COURSE; HUMAN; INFLAMMATION; OBESITY; PROGNOSIS; PROTEIN FUNCTION; REVIEW; TUMOR; VIRUS INFECTION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; NEOPLASMS; OBESITY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; VIRUS DISEASES;

EID: 80052644840     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation [J]. Nat Rev Immunol, 2007, 7: 454-465. (Pubitemid 46834848)
2. Baker BJ, Akhtar LN, Benveniste EN. SOCS1 and SOCS3 in the control of CNS immunity [J]. Trends Immunol, 2009, 30: 392-400.
3. Babon JJ, Sabo JK, Soetopo A, et al. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase [J]. J Mol Biol, 2008, 381: 928-940.
4. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway [J]. Semin Cell Dev Biol, 2008, 19: 414-422.
5. Lang R, Pauleau AL, Parganas E, et al. SOCS3 regulates the plasticity of gp130 signaling [J]. Nat Immunol, 2003, 4: 546-550. (Pubitemid 36701337)
6. McNamee EN, Ryan KM, Griffin EW, et al. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration [J]. Brain Behav Immun, 2010, 24: 660-671.
7. Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation [J]. J Exp Med, 2001, 193: 471-481. (Pubitemid 32524478)
8. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis [J]. J Clin Invest, 2001, 108: 1781-1788. (Pubitemid 34015123)
9. Wong PK, Egan PJ, Croker BA, et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis [J]. J Clin Invest, 2006, 116: 1571-1581.
10. Jo D, Liu D, Yao S, et al. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis [J]. Nat Med, 2005, 11: 892-898. (Pubitemid 41161123)
11. Smith PD, Sun F, Park KK, et al. SOCS3 deletion promotes optic nerve regeneration in vivo [J]. Neuron, 2009, 64: 617-623.
12. Okada S, Nakamura M, Katoh H, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury [J]. Nat Med, 2006, 12: 829-834. (Pubitemid 44050074)
13. Egwuagu CE, Yu CR, Zhang M, et al. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance [J]. J Immunol, 2002, 168: 3181-3187. (Pubitemid 34250377)
14. Seki Y, Inoue H, Nagata N, et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses [J]. Nat Med, 2003, 9: 1047-1054. (Pubitemid 37021785)
15. Ekelund E, Saaf A, Tengvall-Linder M, et al. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis [J]. Am J Hum Genet, 2006, 78: 1060-1065. (Pubitemid 43787697)
16. Koeberlein B, zur HA, Bektas N, et al. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver [J]. Virus Res, 2010, 148: 51-59.
17. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 [J]. Gut, 2006, 55: 529-535.
18. Bode JG, Ludwig S, Ehrhardt C, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3 [J]. FASEB J, 2003, 17: 488-490.
19. Vlotides G, Sorensen AS, Kopp F, et al. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2, 5-OAS and MxA [J]. Biochem Biophys Res Commun, 2004, 320: 1007-1014. (Pubitemid 38887243)
20. Huang Y, Feld JJ, Sapp RK, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C [J]. Gastroenterology, 2007, 132: 733-744. (Pubitemid 46274665)
21. Persico M, Capasso M, Russo R, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C [J]. Gut, 2008, 57: 507-515. (Pubitemid 351442535)
22. Kim KA, Lin W, Tai AW, et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection [J]. J Hepatol, 2009, 50: 705-711.
23. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy [J]. Hepatology, 2007, 46: 1009-1015. (Pubitemid 350144765)
24. Yajima T, Yasukawa H, Jeon ES, et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling [J]. Circulation, 2006, 114: 2364-2373. (Pubitemid 44847453)
25. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight [J]. Nature, 2006, 443: 289-295. (Pubitemid 44435142)
26. You J, Yu Y, Jiang L, et al. Signaling through Tyr985 of leptin receptor as an age/diet-dependent switch in the regulation of energy balance [J]. Mol Cell Biol, 2010, 30: 1650-1659.
27. Munzberg H, Flier JS, Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice [J]. Endocrinology, 2004, 145: 4880-4889. (Pubitemid 39551104)
28. Peralta S, Carrascosa JM, Gallardo N, et al. Ageing increases SOCS-3 expression in rat hypothalamus: effects of food restriction [J]. Biochem Biophys Res Commun, 2002, 296: 425-428.
29. Mori H, Hanada R, Hanada T, et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity [J]. Nat Med, 2004, 10: 739-743. (Pubitemid 38937640)
30. Reed AS, Linger EK, Olofsson LE, et al. Functional role of suppressor of cytokine signaling 3 upregulation in hypothalamic leptin resistance and long-term energy homeostasis [J]. Diabetes, 2010, 59: 894-906.
31. Howard JK, Cave BJ, Oksanen LJ, et al. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3 [J]. Nat Med, 2004, 10: 734-738. (Pubitemid 38937639)
32. Torisu T, Sato N, Yoshiga D, et al. The dual function of hepatic SOCS3 in insulin resistance in vivo [J]. Genes Cells, 2007, 12: 143-154. (Pubitemid 46152654)
33. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 is an insulin-induced negative regulator of insulin signaling [J]. J Biol Chem, 2000, 275: 15985-15991. (Pubitemid 30366903)
34. Nieto-Vazquez I, Fernandez-Veledo S, De Alvaro C, et al. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle [J]. Diabetes, 2008, 57: 3211-3221.
35. Rodriguez-Calvo R, Serrano L, Coll T, et al. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2 [J]. Diabetes, 2008, 57: 2149-2157.
36. Rigby RJ, Simmons JG, Greenhalgh CJ, et al. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon [J]. Oncogene, 2007, 26: 4833-4841. (Pubitemid 47093177)
37. Campbell JS, Prichard L, Schaper F, et al. Expression of suppressors of cytokine signaling during liver regeneration [J]. J Clin Invest, 2001, 107: 1285-1292. (Pubitemid 32494545)
38. Riehle KJ, Campbell JS, McMahan RS, et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3 [J]. J Exp Med, 2008, 205: 91-103. (Pubitemid 351185718)
39. Cui Q, Jiang W, Wang Y, et al. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma [J]. Hepatology, 2008, 47: 105-112. (Pubitemid 351171047)
40. + T lymphocytes in lung tissue via up-regulating Notch1 expression [J]. Cancer Res, 2009, 69: 1578-1586.
41. Lesinski GB, Zimmerer JM, Kreiner M, et al. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells [J]. BMC Cancer, 2010, 10: 142.
42. Zhang Z, Liu Q, Che Y, et al. Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3 [J]. Cancer Res, 2010, 70: 89-98.
43. Zimmerer JM, Lesinski GB, Kondadasula SV, et al. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins [J]. J Immunol, 2007, 178: 4832-4845. (Pubitemid 46595265)
44. Sakai I, Takeuchi K, Yamauchi H, et al. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells [J]. Blood, 2002, 100: 2926-2931.
45. Orr SJ, Morgan NM, Elliott J, et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover [J]. Blood, 2007, 109: 1061-1068. (Pubitemid 46220652)
46. Kamezaki K, Shimoda K, Numata A, et al. Roles of Stat3 and ERK in G-CSF signaling [J]. Stem Cells, 2005, 23: 252-263. (Pubitemid 40239520)
47. Chaligne R, Tonetti C, Besancenot R, et al. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocyte growth in primary myelofibrosis [J]. Leukemia, 2009, 23: 1186-1190.
48. Ruan M, Pederson L, Bradley EW, et al. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis [J]. Endocrinology, 2010, 151: 1713-1722.
49. Wang J, Li XJ. Drug targets discovery based on dynamic signal transduction networks [J]. Acta Pharm Sin, 2010, 45: 1-8.